K. Benmammar

Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

C. Lambert, S. Melnikov, O. Bouché, 2021, Frontiers in Pharmacology.

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

Nancy E. Marion, B. Delclaux, B. Asselain, 2022, The Lancet regional health. Europe.

Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Frédérique Penault-Llorca, F. Penault-Llorca, N. Radosevic-Robin, 2015, Critical reviews in oncology/hematology.

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

F. Penault-Llorca, N. Radosevic-Robin, T. Petit, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

O. Bouché, N. Kerckhove, M. Selvy, 2020, Journal of clinical medicine.

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial

B. Weber, F. Penault-Llorca, N. Radosevic-Robin, 2014 .

Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.

N. Kerckhove, M. Selvy, Coralie Gonneau, 2024, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer

F. Penault-Llorca, N. Radosevic-Robin, M. Mouret-Reynier, 2016, International journal of cancer.